Is cabozantinib a targeted drug?

Yes, cabozantinib (Cabozantinib) is a targeted drug. Targeted drugs refer to the intervention of specific molecules or signaling pathways in tumor cells through a specific mechanism of action, thereby inhibiting the growth, proliferation and metastasis of tumor cells while minimizing damage to normal cells. Cabozantinib is a multi-target tyrosine kinase inhibitor that acts on a variety of receptor kinases and receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGF R3), hepatocyte growth factor receptor (HGFR or c-Met), tumor-derived growth factor receptor (RET), etc. These receptors play critical roles in tumor growth, angiogenesis, metastasis, and progression.